Atrial Fibrillation and Stroke Prevention and Management in CKD
Clinical Journal of the American Society of Nephrology · 2026-11 · 21 (11) · 2015-2024
DOI: 10.2215/cjn.0000001159 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Clinical Journal of the American Society of Nephrology, online erschienen am 23.06.2026. Verfasst von Nisha Bansal und 7 weiteren Autor:innen. Beteiligte Einrichtung: Division of Nephrology, University of Washington, Seattle, Washington. Hauptthemen laut MEDLINE: Atrial Fibrillation, Stroke, Renal Insufficiency, Chronic. Die Arbeit nennt 91 Literaturangaben. Gefördert von: NIDDK NIH HHS, National Institute of Diabetes and Digestive and Kidney Diseases.
Themen: Schlaganfall
Abstract (Originalsprache)
Atrial fibrillation (AF) is the most common sustained arrhythmia, with a prevalence and incidence significantly higher in adults with CKD compared with the general population. This risk increases with reduced kidney function, affecting up to 25% of all patients with CKD and 30% of those on receiving chronic dialysis. AF is associated with increased morbidity and mortality, including higher risks of stroke, heart failure, myocardial dysfunction, and progression to kidney failure. The bidirectional relationship between AF and CKD is driven by a convergence of traditional risk factors—such as hypertension and diabetes—and CKD-specific abnormalities. Key pathophysiologic mechanisms include systemic inflammation, oxidative stress, autonomic dysfunction, and disordered mineral metabolism. These factors promote structural remodeling, atrial fibrosis, and electrical instability, creating a highly arrhythmogenic substrate. Treatment options for AF include anticoagulation, rate and rhythm control medications, other cardiovascular therapies ( e.g ., sodium glucose cotransporter 2 inhibitors), and procedures aimed at normalizing rhythm and reducing stroke risk. Patients with CKD are often undertreated with AF medications and procedures, in part because of lack of robust randomized clinical trial data on efficacy and safety, particularly with advanced CKD. This narrative review summarizes key literature on the epidemiology, risk factors, mechanisms and treatment of AF in adults with CKD, and highlights critical areas for future research.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Nephrology, University of Washington, Seattle, Washington.
- Nephrology Division, NYU Grossman, New York, New York.
- Department of Medicine, Epidemiology and Biostatistics, Schulich School of Medicine and Dentistry, Western University, London, Ontario, Canada.
- London Health Sciences Centre Research Institute, London, Ontario, Canada.
- Division of General Internal Medicine, Mass General Brigham Healthcare, Boston, Massachusetts.
- Harvard Medical School, Boston, Massachusetts.
ORCID-Profile: Nisha Bansal, David M Charytan, Amit X Garg, Elsayed Z Soliman, Manish M Sood, Alan S Go
Förderung
- NIDDK NIH HHS
- National Institute of Diabetes and Digestive and Kidney Diseases
Zitieren
APA
Bansal, N., Charytan, D. M., Garg, A. X., Singer, D. E., Soliman, E. Z., Sood, M. M., Winkelmayer, W. C., & Go, A. S. (2026). Atrial Fibrillation and Stroke Prevention and Management in CKD. Clinical Journal of the American Society of Nephrology, 21(11), 2015-2024. https://doi.org/10.2215/cjn.0000001159
Vancouver
Bansal N, Charytan DM, Garg AX, Singer DE, Soliman EZ, Sood MM, et al. Atrial Fibrillation and Stroke Prevention and Management in CKD. Clinical Journal of the American Society of Nephrology. 2026;21(11):2015-2024. doi:10.2215/cjn.0000001159
BibTeX
@article{Bansal2026,
author = {Bansal, Nisha and Charytan, David M and Garg, Amit X and Singer, Daniel E and Soliman, Elsayed Z and Sood, Manish M and Winkelmayer, Wolfgang C and Go, Alan S},
title = {Atrial Fibrillation and Stroke Prevention and Management in CKD},
journal = {Clinical Journal of the American Society of Nephrology},
year = {2026},
volume = {21},
number = {11},
pages = {2015--2024},
doi = {10.2215/cjn.0000001159}
}
EUVIMED